Based on the predictive value of HER2 mRNA levels and on basis of the above-described differences in ER-positive and ER-negative tumors, we performed GSEA in the GHEA cohort to define pathways correlated with HER2 mRNA levels in BC according to ER positivity. The gene discussed is ESR1; the disease is breast cancer.